Opus Genetics (NASDAQ:IRD) CFO Robert Gagnon Sells 7,842 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD) CFO Robert Gagnon sold 7,842 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total value of $40,621.56. Following the sale, the chief financial officer directly owned 592,158 shares of the company’s stock, valued at approximately $3,067,378.44. This represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Opus Genetics Price Performance

Shares of NASDAQ IRD opened at $5.12 on Tuesday. Opus Genetics, Inc. has a 1-year low of $0.81 and a 1-year high of $5.81. The stock has a fifty day moving average price of $4.70 and a 200 day moving average price of $3.09. The company has a market cap of $365.57 million, a PE ratio of -6.24 and a beta of 0.52.

Analyst Ratings Changes

IRD has been the subject of a number of recent analyst reports. Oppenheimer initiated coverage on Opus Genetics in a report on Monday, March 16th. They issued an “outperform” rating and a $10.00 target price for the company. Chardan Capital raised their target price on Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a report on Tuesday, April 21st. Lifesci Capital raised Opus Genetics to a “strong-buy” rating in a report on Thursday, February 12th. Finally, Craig Hallum set a $9.00 target price on Opus Genetics and gave the company a “buy” rating in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Opus Genetics presently has an average rating of “Moderate Buy” and an average target price of $10.11.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Neutral Sentiment: Management will present at several ophthalmology and industry conferences in May 2026, maintaining visibility with investors and the research community; this is routine corporate outreach rather than an immediate clinical readout. Opus Genetics to Participate in Leading Medical Conferences in May 2026
• Negative Sentiment: Multiple insiders sold stock on April 23rd (CEO George Magrath, CFO Robert Gagnon, COO Joseph Schachle, President Benjamin Yerxa, and others). Combined sales total tens of thousands of shares at roughly $5.18–$5.24 per share. While the company discloses these were sales to cover tax withholding on vested awards (reducing the likelihood of a signal of loss of confidence), clustered insider selling can pressure the share price and likely contributed to today’s weakness. SEC filings: CEO sale CEO Form 4, CFO sale CFO Form 4, other insider filings available in SEC disclosures.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC raised its stake in shares of Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after buying an additional 1,435,407 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Opus Genetics during the 4th quarter worth $5,463,000. Millennium Management LLC acquired a new position in shares of Opus Genetics during the 4th quarter worth $4,025,000. Mink Brook Asset Management LLC raised its stake in shares of Opus Genetics by 34.5% during the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after buying an additional 427,684 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Opus Genetics by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock worth $2,214,000 after buying an additional 349,825 shares during the last quarter. Institutional investors and hedge funds own 14.97% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.